All trading involves risk. Losses can exceed deposits.

Tuesday morning snapshot

A snapshot of the early morning's equity news and key market movements.

All trading involves risk. Losses can exceed deposits.

Last night in the US: The Dow Jones closed up 40  points at 16,449, the NASDAQ finished up 25 points at 3559 and the S&P 500 ended the day up seven points at 1871.

This morning in London: The FTSE 100 is currently up 58 points at 6683.

FX and commodities: GBP/USD is up 22 pips at $1.6813, EUR/USD is up ten pips at $1.3803 and USD/JPY is down ten pips at ¥102.51. Brent crude is down eight cents at $109.91 and gold is trading at $1289, down $1.

Stocks: GlaxoSmithKline will return £4 billion to its shareholders after it struck a deal with Swiss drug maker Novartis to exchange assets. Pharmaceutical company AstraZeneca is believed to be in takeover talks with Pfizer.

The day ahead: In the US, the house price index is due out at 2pm followed by existing home sales and the Richmond manufacturing index at 3pm.

All figures correct at 8.15am. All times London time.

This information has been prepared by IG, a trading name of IG Markets Limited. In addition to the disclaimer below, the material on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication. Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients. See full non-independent research disclaimer and quarterly summary.